Onureg (azacitidine)

pCPA File Number: 21641
Negotiation Status:
Under consideration for negotiation
Indication(s):
Maintenance therapy in adult patients with acute myeloid leukemia (AML) who achieved complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following induction therapy with or without consolidation treatment, and who are not eligible for hematopoietic stem cell transplantation (HSCT)
Sponsor/Manufacturer:
Celgene Inc.
CADTH Project Number:
PC0245-000
pCPA Engagement Letter Issued:
Not Applicable
Negotiation Process Concluded:
Not Applicable